Sage's depression drug moves closer to approval, shares soar

Adjust Comment Print

Sage Therapeutics shares are once again rocketing up this morning, this time based on positive results from a small Phase II study of an oral version of their depression therapy.

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. Rhumbline Advisers accumulated 41,138 shares. State Common Retirement Fund reported 0% of its portfolio in Sage Therapeutics, Inc. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. (NASDAQ:SAGE) has "Buy" rating given on Tuesday, September 5 by Cowen & Co. (NASDAQ:SAGE). Tiaa Cref Inv Mgmt Ltd Llc reported 122,554 shares. (NASDAQ:SAGE). Jabre Sa has invested 0.03% of its portfolio in Sage Therapeutics, Inc. (NASDAQ:SAGE) on Friday, November 10 to "Buy" rating. For the quarter, shares have been noted at 6.13%. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,378 shares of the biopharmaceutical company's stock worth $110,000 after acquiring an additional 138 shares in the last quarter. The business had revenue of $8.78 million during the quarter. equities research analysts anticipate that Protagonist Therapeutics Inc will post -3.66 EPS for the current fiscal year. Therefore 88% are positive. The stock now has an average rating of "Buy" and a consensus target price of $130.64. Taking under account analyst expectations, the 12-month average price target stands at $117.50, marking a almost 28% downside from where the stock is now trading. It has outperformed by 99.75% the S&P500. SAGE Therapeutics had 45 analyst reports since September 3, 2015 according to SRatingsIntel. On Thursday, November 9 the stock rating was maintained by Cowen & Co with "Buy". Chardan Capital Markets upgraded Sage Therapeutics, Inc. The firm has "Outperform" rating by BMO Capital Markets given on Wednesday, June 29. The firm has "Buy" rating given on Tuesday, September 12 by Needham. Leerink Swann maintained the shares of SAGE in report on Thursday, September 3 with "Buy" rating. The company was initiated on Tuesday, September 13 by Raymond James.

More recent Sage Therapeutics, Inc. (NASDAQ:SAGE) news were published by: Realmoney.Thestreet.com which released: "Sage Therapeutics Skyrockets on Data for Depression Drug - Biotech Movers" on December 07, 2017, also Cnbc.com with their article: "Sage Therapeutics shares soar after postpartum depression drug meets main goal" published on November 09, 2017, Businesswire.com published: "Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635 (c)(4)" on December 04, 2017.

PDP State Chair, Sango, son's abductors demand N100m
Sango, a serial governorship aspirant, is the current Chairman of the Peoples Democratic Party, PDP , in Plateau State. We want to know if they (abductees) are alive and in good condition.


Praising the depression drug's safety profile, the analyst elaborates: "Safety clean, highly encouraging SAGE-217 showed a clean safety profile with adverse events consistent with prior studies, including headache, dizziness, nausea, and somnolence". The correct version of this news story can be accessed at https://www.truebluetribune.com/2017/12/07/northern-trust-corp-purchases-19159-shares-of-protagonist-therapeutics-inc-ptgx.html. Sage Therapeutics, Inc. (NASDAQ:SAGE) has risen 116.45% since December 7, 2016 and is uptrending. But back-to-back successes have since then more than doubled the share price, adding billions in market cap.

Protagonist Therapeutics, Inc is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. There has been little innovation in depression treatments in the last two decades, he said. It now has negative earnings.

Sage Therapeutics (NASDAQ:SAGE) is up 52% premarket on light volume in response to its announcement of positive results from a Phase 2 clinical trial assessing SAGE-217 for the treatment of adult patients with moderate-to-severe major depressive disorder (MDD), a Fast Track indication in the U.S.

Comments